Generation of KS-133 as a Novel Bicyclic Peptide with a Potent and Selective VIPR2 Antagonist Activity that Counteracts Cognitive Decline in a Mouse Model of Psychiatric Disorders

Generation of KS-133 as a Novel Bicyclic Peptide with a Potent and Selective VIPR2 Antagonist Activity that Counteracts Cognitive Decline in a Mouse Model of Psychiatric Disorders

Worldwide, more than 20 million people suffer from schizophrenia, but effective and definitive new therapeutic drugs/treatments have not been established. Vasoactive intestinal peptide receptor 2 (VIPR2) might be an attractive drug target for the treatment of schizophrenia because both preclinical a...

Full description

Saved in:
Bibliographic Details
Main Authors: Kotaro Sakamoto, Lu Chen, Tatsunori Miyaoka, Mei Yamada, Teruaki Masutani, Kenji Ishimoto, Nobumasa Hino, Shinsaku Nakagawa, Satoshi Asano, Yukio Ago
Format: article
Language:EN
Published: Frontiers Media S.A. 2021
Subjects:
KS-133
VIPR2/VPAC2
cyclic peptide
bicyclization
antagonist
schizophrenia
Therapeutics. Pharmacology
RM1-950
Online Access:https://doaj.org/article/a48f0731bf1640b887ab23400b1a5cfb
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/a48f0731bf1640b887ab23400b1a5cfb

Similar Items